Lack of pharmacokinetic interaction after administration of lansoprazole or omeprazole with prednisone

Journal of Clinical Pharmacology

Volumn 36, Issue 11, 1996, Pages 1064-1071

  Cavanaugh, John H ^a   Karol, Michael D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; PREDNISOLONE; PREDNISONE; PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; ADULT; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG DISPOSITION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PEMPHIGUS; RANDOMIZED CONTROLLED TRIAL; STEROID THERAPY; STOMACH ULCER;

EID: 0030469828     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127009603601110     Document Type: Article

References (34)

1. Muller P, Dammann HG, Leucht U, Simon B: Human gastric acid secretion following repeated doses of AG-1749. Aliment Pharmacol Ther 1989;3:193-198.
2. Brunner G, Arnold R, Hennig U, Fuchs W: An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther 1993;7(suppl 1):51-55.
3. Lanza F, Goff J, Scowcroft C, Jennings D, Greski-Rose P: Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Am J Gastroenterol 1994; 89:1191-1200.
4. +-ATPase inhibitor: a controlled, double-blind study. Am J Gastroenterol 1993;88:1212-1217.
5. Jensen RT, Metz DC, Koviack PD, Feigenbaum KM: Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1993;7(suppl 1):41-50.
6. Iwahi T, Satoh H, Nakao M, Iwasaki T, Yamazaki T, Kubo K, et al: Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991;35:490-496.
7. Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeaux H, et al: Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 1995;47:410-418.
8. Andersson T: Omeprazole drug interaction studies. Clin Pharmacokinet 1991;21:195-212.
9. Chosidow O, Joly P, Laurent Puig P, Prost C, Espaagne E, Wechsler J, et al: Pemphigoide Bulleuse Secondairement Corticoresistante: Role inhibiteur de l'omeprazole sur le metabolisme des corticoides? Ann Dermatol Venereol 1991;118:45-46.
10. Joly P, Chosidow O, Laurent-Puig P, Delchier J-C, Roujeau J-C, Revuz J, et al: Possible interaction prednisone-omeprazole dans la pemphigoïe bulleuse. Gastroenterologie Clinique et Biologique 1990;14:682-683.
11. Locke C: Use of a more general model for bioavailability studies. Commun Statist-Theory Mathematics 1990;19:3361-3373.
12. United States Department of Health and Human Services: "COSTART" Coding Symbols for Thesaurus of Adverse Reaction Terms. Third edition. Rockville, MD: United States Department of Health and Human Services, 1989.
13. SAS Institute: SAS/STAT User's Guide: Statistics. Version 6, Volume 2. Cary, NC: SAS Institute, 1990.
14. Andersson T, Andren K, Cederberg C: Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol 1990;39:51-54.
15. Naidu MUR, Shobha JC, Dixit VK: Effect of multiple dose omeprazole on the pharmacokinetics of carbamazepine. Drug Invest 1994;7:8-12.
16. Henry DA, Somerville KW, Kirchingman G, Langman NJ: Omeprazole effects on oxidative drug metabolism. Br J Clin Pharmacol 1984;18:195-200.
17. Gugler R, Jensen JC: Omeprazole inhibits oxidative drug metabolism studies with diazepam in phenytoin in vivo and 7-ethoxycoumarin in vivo. Gastroenterology 1985;89:1235-1241.
18. Prichard PJ, Walt RP, Kitchingman GK: Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol 1987;24:543-545.
19. Sutfin T, Balmer K, Bostrom H, Eriksson S, Huglund P, Paulsen O: Stereoselective interactive of omeprazole with warfarin in healthy men. Ther Drug Monit 1989;11:176-184.
20. Soons PA, van den Berg G, Danhof M, van Brummelen P, Jansen JBMJ, Lamers CBHW, Breimer DD: Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects. Eur J Clin Pharmacol 1992;42:319-324.
21. Schouler LF, Dumas P, Couzigou P, Janvier G, Winnock S, Saric J: Omeprazole-cyclosporin interaction. Am J Gastroenterol 1991;86:1097.
22. Lefebvre RA, Flouvat B, Karolac-Tamisier S, Moerman E, Van Ganse E: Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther 1992;52:458-463.
23. Karol MD, Mukherji D, Cavanaugh JH: Lack of effect of concomitant multi-dose lansoprazole on single-dose phenytoin pharmacokinetics in subjects (abstract). Gastroenterology 1994; 106:A103.
24. Cavanaugh JH, Park YK, Awni WM, Mukherjee DX, Karol MD, Granneman GR: Effect of lansoprazole on antipyrine and ICG pharmacokinetics (abstract). Gastroenterology 1991;100:A40.
25. Braeckman RA, Winters EP, Cohen A, Locke CS, Cavanaugh JP: Lack of effect of lansoprazole on warfarin pharmacokinetics and anticoagulation effect in healthy subjects (abstract). Pharm Res 1991;8(suppl):S295.
26. Cavanaugh JH, Winters EP, Cohen A, Locke CS, Braeckman R: Lack of effect of lansoprazole on steady state warfarin metabolism (abstract). Gastroenterology 1991;100:A40.
27. Cavanaugh JH, Schneck DW, Mukherji D, Karol MD: Lack of effect of concomitant lansoprazole on single-dose propranolol pharmacokinetics and pharmacodynamics (abstract). Gastroenterology 1994;106:A4.
28. Fuchs W, Sennewald R, Klotz U: Lansoprazole does not affect the bioavailability of oral contraceptives. Br J Clin Pharmacol 1994;38:376-380.
29. Granneman G, Winters EP, Locke CS, Leese PT, Karol MD, Cavanaugh JH: Lack of effect of concomitant lansoprazole on steady-state theophylline pharmacokinetics (abstract). Gastroenterology 1991;100:A75.
30. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A: Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 1996;277:805-816.
31. Pichard L, Curi-Pedrosa R, Bonfils C, Jacqz-Aigrain E, Domergue J, Joyeux H, et al: Oxidative Metabolism of Lansoprazole by Human Liver Cytochromes P450. Mol Pharmacol 1995;47:410-418.
32. Spatzenegger M, Jaeger W: Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metab Rev 1995;27:397-417.
33. Frey BM, Frey FJ: Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 1990;19:126-146.
34. Rodrigues AD, Freston JW: Do PPI effects on the cytochrome P450 system have implications to significant drug interactions? In, Giuli R, Tytgat GNJ, DeMeester TR, Galmiche JP (eds.): The Esophageal Mucosa: 300 Questions, 300 Answers. New York: Elsevier, 1994;460-464.